| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.028 | 0.9 |